To provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 7% | 20.31% | 21.85% | 16% | 12.88% | 16.36% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 14.52% | 74.21% | 120.53% | 110.13% | 235.87% | 6169.7% |
| Rank within category | 12/19 | 12/18 | 7/18 | 5/18 | 7/17 | 4/14 | 2/12 | 1/10 | 1/9 | 2/4 | N/A |
| Sector Funds | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | -14.02% | 2.06% | -9.89% | -0.49% | 65.84% | 20.15% | -6.02% | 38.24% | 42.22% | -3.5% | 14.43% |
| Q1 returns | -11.31% | 6.25% | -11.2% | 0.34% | -4.18% | -0.75% | -6.29% | -2.23% | 11.71% | -5.88% | -1.34% |
| Q2 returns | 1.67% | -8.92% | -2.61% | -9.1% | 27.68% | 18.2% | -9.75% | 18.64% | 4.22% | 5.21% | 18.53% |
| Q3 returns | 5.89% | -3.27% | 9.49% | -0.3% | 22.44% | 1.15% | 8.9% | 8.96% | 17.36% | -2.85% | 2.65% |
| Q4 returns | -9.95% | 9.01% | -4.84% | 9.42% | 10.71% | 1.25% | 2.05% | 9.37% | 4.09% | 0.31% | -4.68% |
0.50% on or before 15D, Nil after 15D
| Alpha | 0.17057 |
| Beta | 0.9004 |
| Sharpe Ratio | 0.331264 |
| Sortino Ratio | 0.75112 |
| R-Squared | 0.9368 |
| Tracking Error | 1.0385 |
| Downside Risk | 15.4301 |
| Std. Deviation (Annualised) | 13.3897 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW Current | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | 15.22% | 11.84% | 12.5% | 11% | 1,511.49 | 2.37 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.14% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.91% |
| TREPS | Cash & Cash Equivalents and Net Assets | 6.42% | |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.03% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 4.45% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.42% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.40% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.05% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 3.80% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.42% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 3.21% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.96% |
| Sudeep Pharma Ltd. | Chemicals & Petrochemicals | Domestic Equities | 2.79% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.75% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.60% |
| CORONA Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.43% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.37% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.36% |
| Concord Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.25% |
| Aether Industries Ltd. | Chemicals & Petrochemicals | Domestic Equities | 2.17% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 2.16% |
| Poly Medicure Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 1.82% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.79% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.74% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.71% |
| Healthcare Global Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.70% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.69% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.66% |
| Innova Captab Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.65% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.62% |
| Nephrocare Health Services Ltd. | Healthcare Services | Domestic Equities | 1.12% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 1.12% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 0.67% |
| Gufic Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.29% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.23% |
| 364 DAY T-BILL 19.11.26 | Treasury Bills | 0.05% | |
| Evonile Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.04% |
| Net Receivable / Payable | Cash & Cash Equivalents and Net Assets | -2.01% | |
| Total | 100.00% | ||
Mr. Desai has close to 6 years of work experience with over 3 years of experience in Indian capital markets. He has been associated with SBI Funds Management Private Limited from May 2008. Prior to join SBI Funds Management Pvt. Ltd. he was a lecturer in Electronics Department with D J Sanghvi College of Engineering, Mumbai.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
